Exploring the impact and challenges of the 'Right to Try' legislation for experimental treatments.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf ...

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune ...

Retail trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ...

Fintel reports that on July 30, 2025, Cantor Fitzgerald upgraded their outlook for Replimune Group (NasdaqGS:REPL) from ...

At the 2025 Alzheimer’s Association International Conference, one of the bigger splashes was made by an experimental cardiovascular drug. Newamsterdam Pharma Co. NV presented data showing that its ...

Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA leadership change. Read more here.

Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

As analysts parsed news of Vinay Prasad’s ouster, worries over drug approval delays, cell and gene therapy impacts and more ...